Companies › Genfleet Therapeutics (Shanghai)
4 active drug programs in 77 registered trials: 49 Phase 2, 14 Phase 1, 14 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cetuximab (GFH375) KRAS G12D inhibitor | KRAS | Phase 3 | Metastatic Pancreatic Cancer; KRAS G12D Mutation; Pancreatic Cancer; Advanced Solid Tumors Cancer … | Jun 2027 |
| GFH276 RAS inhibitor | – | Phase 2 | Pancreatic Cancer; Advanced Solid Tumors Cancer | Nov 2027 |
| GFS202A | – | Phase 2 | Pancreatic Cancer; Cancer Cachexia | Aug 2028 |
| GFH009 | – | Phase 1 | Large B-cell Lymphoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03498378 | Cetuximab (GFH375) | Phase 1 | Head and Neck Squamous Cell Carcinoma | Oncology | Feb 2020 |
| NCT03493048 | Cetuximab (GFH375) | Phase 2 | Colorectal Cancer | Oncology | Dec 2022 |
| NCT03874026 | Cetuximab (GFH375) | Phase 2 | Colorectal Cancer | Oncology | May 2023 |
| NCT05586100 | Cetuximab (GFH375) | Phase 2 | Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma | Oncology | Apr 2025 |
| NCT06279351 | Cetuximab (GFH375) | Phase 2 | Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer | Oncology | Dec 2025 |
| NCT06898255 | GFS202A | Phase 1 | Cancer Cachexia | Oncology | Jun 2026 |
| NCT05312398 | Cetuximab (GFH375) | Phase 2 | Metastatic Colorectal Adenocarcinoma | Oncology | Aug 2026 |
| NCT02270814 | Cetuximab (GFH375) | Phase 2 | Head and Neck Cancer | Oncology | Sep 2026 |
| NCT06998069 | Cetuximab (GFH375) | Phase 3 | Head and Neck Neoplasms | Oncology | Dec 2026 |
| NCT06151743 | Cetuximab (GFH375) | Phase 2 | Locally Advanced Hypopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT01025089 | Cetuximab (GFH375) | Phase 2 | Thymoma | Oncology | Dec 2026 |
| NCT04375384 | Cetuximab (GFH375) | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06005324 | Cetuximab (GFH375) | Phase 1 | HPV-Negative Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT05260671 | Cetuximab (GFH375) | Phase 2 | Head and Neck Neoplasms | Oncology | Dec 2026 |
| NCT05962502 | Cetuximab (GFH375) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT05706779 | Cetuximab (GFH375) | Phase 2 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT06321081 | Cetuximab (GFH375) | Phase 2 | RAS Mutation | Oncology | Dec 2026 |
| NCT06375733 | GFH009 | Phase 1 | Large B-cell Lymphoma | Oncology | Dec 2026 |
| NCT06226857 | Cetuximab (GFH375) | Phase 3 | Colorectal Neoplasms | Oncology | Dec 2026 |
| NCT07257653 | Cetuximab (GFH375) | Phase 2 | Colorectal Neoplasms | Oncology | Dec 2026 |
| NCT06763029 | Cetuximab (GFH375) | Phase 2 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT06239220 | Cetuximab (GFH375) | Phase 2 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT06978829 | Cetuximab (GFH375) | Phase 2 | LA HNSCC | Oncology | Mar 2027 |
| NCT01468896 | Cetuximab (GFH375) | Phase 1 | Metastatic Head and Neck Squamous Cell Carcinoma | Oncology | Mar 2027 |
| NCT04229459 | Cetuximab (GFH375) | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Apr 2027 |
| NCT06411600 | Cetuximab (GFH375) | Phase 2 | Metastatic Colorectal Cancer | Oncology | May 2027 |
| NCT07559760 | Cetuximab (GFH375) | Phase 2 | Metastatic Colorectal Cancer | Oncology | May 2027 |
| NCT07262567 | Cetuximab (GFH375) | Phase 3 | Metastatic Pancreatic Cancer | Oncology | Jun 2027 |
| NCT07259590 | Cetuximab (GFH375) | Phase 1 | Advanced Solid Tumors Cancer | Oncology | Jul 2027 |
| NCT06869473 | Cetuximab (GFH375) | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Oncology | Aug 2027 |
| NCT07198841 | Cetuximab (GFH375) | Phase 2 | Lung Cancer (Non-Small Cell) | Oncology | Sep 2027 |
| NCT04687631 | Cetuximab (GFH375) | Phase 3 | Colorectal Cancer | Oncology | Sep 2027 |
| NCT06978400 | Cetuximab (GFH375) | Phase 2 | Neoplasms | Oncology | Nov 2027 |
| NCT07678593 | GFH276 | Phase 1 | Advanced Solid Tumors Cancer | Oncology | Nov 2027 |
| NCT02999087 | Cetuximab (GFH375) | Phase 3 | HNSCC | Oncology | Dec 2027 |
| NCT07506109 | Cetuximab (GFH375) | Phase 2 | BRAF V600E | Oncology | Dec 2027 |
| NCT04017650 | Cetuximab (GFH375) | Phase 1 | BRAF NP_004324.2:p.V600E | Oncology | Dec 2027 |
| NCT01154920 | Cetuximab (GFH375) | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2027 |
| NCT03391843 | Cetuximab (GFH375) | Phase 2 | Rectal Cancer Stage III | Oncology | Dec 2027 |
| NCT07012954 | Cetuximab (GFH375) | Phase 1 | Colorectal Cancer Metastatic | Oncology | Dec 2027 |
| NCT07063212 | Cetuximab (GFH375) | Phase 2 | Squamous Cell Carcinoma of Head and Neck | Oncology | Jan 2028 |
| NCT06725368 | Cetuximab (GFH375) | Phase 2 | Head and Neck Cancer | Oncology | Jan 2028 |
| NCT06855212 | Cetuximab (GFH375) | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Mar 2028 |
| NCT06477692 | Cetuximab (GFH375) | Phase 2 | Head and Neck Cancer | Oncology | Jul 2028 |
| NCT06500676 | Cetuximab (GFH375) | Phase 1 | KRAS G12D Mutations | Oncology | Jul 2028 |
| NCT07784374 | GFH276 | Phase 2 | Pancreatic Cancer | Oncology | Aug 2028 |
| NCT07784374 | GFS202A | Phase 2 | Pancreatic Cancer | Oncology | Aug 2028 |
| NCT07784374 | Cetuximab (GFH375) | Phase 2 | Pancreatic Cancer | Oncology | Aug 2028 |
| NCT06440902 | Cetuximab (GFH375) | Phase 2 | Colorectal Cancer Metastatic | Oncology | Sep 2028 |
| NCT05041127 | Cetuximab (GFH375) | Phase 2 | Chordoma | Oncology | Sep 2028 |
| NCT06856213 | Cetuximab (GFH375) | Phase 2 | Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma | Oncology | Oct 2028 |
| NCT07882888 | Cetuximab (GFH375) | Phase 2 | Head and Neck Cancer | Oncology | Oct 2028 |
| NCT03944941 | Cetuximab (GFH375) | Phase 2 | Skin Squamous Cell Carcinoma | Oncology | Dec 2028 |
| NCT07581912 | Cetuximab (GFH375) | Phase 2 | Colorectal Cancer | Oncology | Dec 2028 |
| NCT02861898 | Cetuximab (GFH375) | Phase 1 | Glioblastoma | Oncology | Dec 2028 |
| NCT04616183 | Cetuximab (GFH375) | Phase 1 | Metastatic Colon Adenocarcinoma | Oncology | Dec 2028 |
| NCT06412198 | Cetuximab (GFH375) | Phase 1 | Metastatic Colorectal Cancer | Oncology | Mar 2029 |
| NCT06207656 | Cetuximab (GFH375) | Phase 2 | Colorectal Cancer | Oncology | Apr 2029 |
| NCT07549399 | Cetuximab (GFH375) | Phase 3 | Rectal Adenocarcinoma | Oncology | Apr 2029 |
| NCT05863195 | Cetuximab (GFH375) | Phase 3 | Metastatic Colorectal Carcinoma | Oncology | Jun 2029 |
The 60 nearest readouts of 77 trials; the rest in the app.
Kumquat Biosciences Ranok Therapeutics (Hangzhou) Vividion Therapeutics Blueprint Medicines InxMed (Shanghai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.